-
1
-
-
5644252971
-
Molecular approach to breast cancer treatment
-
Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol 2004;31 Suppl 10:6-13.
-
(2004)
Semin Oncol
, vol.31
, Issue.SUPPL. 10
, pp. 6-13
-
-
Yarden, Y.1
Baselga, J.2
Miles, D.3
-
2
-
-
18344390418
-
ErbB receptors and cancer: The complexity of targeted inhibitors
-
Hynes NE, Lane HA. ErbB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 341
-
-
Hynes, N.E.1
Lane, H.A.2
-
3
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
4
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
-
5
-
-
0024478054
-
p185HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
-
Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
-
(1989)
Mol Cell Biol
, vol.9
, pp. 1165-1172
-
-
Hudziak, R.M.1
Lewis, G.D.2
Winget, M.3
Fendly, B.M.4
Shepard, H.M.5
Ullrich, A.6
-
6
-
-
0026610881
-
Humanization of an anti-p185HER-2 antibody for human cancer therapy
-
Carter P, Presta L, Gorman CM, Ridgway JB, Hermer D, Wong WL, et al. Humanization of an anti-p185HER-2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
-
(1992)
Proc Natl Acad Sci U S A
, vol.89
, pp. 4285-4289
-
-
Carter, P.1
Presta, L.2
Gorman, C.M.3
Ridgway, J.B.4
Hermer, D.5
Wong, W.L.6
-
7
-
-
10744230127
-
An open-and-shut case? Recent insights into the activation of EGF/ ErbB receptors
-
Burgessi AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ ErbB receptors. Mol Cell 2003;12:541-52.
-
(2003)
Mol Cell
, vol.12
, pp. 541-552
-
-
Burgessi, A.W.1
Cho, H.S.2
Eigenbrot, C.3
Ferguson, K.M.4
Garrett, T.P.5
Leahy, D.J.6
-
8
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
-
(2002)
J Clin Oncol
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
Gutheil, J.C.4
Harris, L.N.5
Fehrenbacher, L.6
-
10
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
-
11
-
-
17144371333
-
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
-
Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2162-2171
-
-
Baselga, J.1
Carbonell, X.2
Castaneda-Soto, N.J.3
Clemens, M.4
Green, M.5
Harvey, V.6
-
12
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001;344:783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
-
13
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-74.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
Snyder, R.4
Mauriac, L.5
Tubiana-Hulin, M.6
-
14
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005;353:1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer Jr, C.E.5
Davidson, N.E.6
-
15
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med 2005;353:1659-72.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
-
16
-
-
33645720799
-
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study
-
December 8-11, ABstract
-
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium (December 8-11, 2005):ABstract 1.
-
(2005)
28th Annual San Antonio Breast Cancer Symposium
, pp. 1
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
Pienkowski, T.4
Martin, M.5
Pawlicki, M.6
-
17
-
-
5144226211
-
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
-
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
-
(2004)
Cancer Cell
, vol.6
, pp. 117-127
-
-
Nagata, Y.1
Lan, K.H.2
Zhou, X.3
Tan, M.4
Esteva, F.J.5
Sahin, A.A.6
-
18
-
-
0035915421
-
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
-
Lu Y, Zi Y, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 1852-1857
-
-
Lu, Y.1
Zi, Y.2
Zhao, Y.3
Mascarenhas, D.4
Pollak, M.5
-
19
-
-
0036187710
-
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
-
Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002;8:347-53.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 347-353
-
-
Molina, M.A.1
Saez, R.2
Ramsey, E.E.3
Garcia-Barchino, M.J.4
Rojo, F.5
Evans, A.J.6
-
20
-
-
0032532950
-
NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
-
Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, et al. NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998;58:5123-9.
-
(1998)
Cancer Res
, vol.58
, pp. 5123-5129
-
-
Christianson, T.A.1
Doherty, J.K.2
Lin, Y.J.3
Ramsey, E.E.4
Holmes, R.5
Keenan, E.J.6
-
21
-
-
0033559210
-
Cleavage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells
-
Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999;59:1196-201.
-
(1999)
Cancer Res
, vol.59
, pp. 1196-1201
-
-
Codony-Servat, J.1
Albanell, J.2
Lopez-Talavera, J.C.3
Arribas, J.4
Baselga, J.5
-
22
-
-
33746290773
-
Biosynthesis of tumorigenic HER-2 C-terminal fragments by alternative initiation of translation
-
Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo, FR, Baselga J, et al. Biosynthesis of tumorigenic HER-2 C-terminal fragments by alternative initiation of translation. EMBO J 2006;25:3234-44.
-
(2006)
EMBO J
, vol.25
, pp. 3234-3244
-
-
Anido, J.1
Scaltriti, M.2
Bech Serra, J.J.3
Santiago Josefat, B.4
Todo, F.R.5
Baselga, J.6
-
23
-
-
4644289313
-
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
-
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64: 6652-9.
-
(2004)
Cancer Res
, vol.64
, pp. 6652-6659
-
-
Wood, E.R.1
Truesdale, A.T.2
McDonald, O.B.3
Yuan, D.4
Hassell, A.5
Dickerson, S.H.6
-
24
-
-
23944476155
-
Phase I safety, pharmacokinetics, and clinical activity study of Lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of Lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5305-5313
-
-
Burris 3rd, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
Dowlati, A.4
Blackwell, K.L.5
O'Neil, B.6
-
25
-
-
0030027934
-
-
Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996;20:102-4, 106, 108-10.
-
Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996;20:102-4, 106, 108-10.
-
-
-
-
26
-
-
0035874981
-
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
-
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9.
-
(2001)
Cancer Res
, vol.61
, pp. 4744-4749
-
-
Molina, M.A.1
Codony-Servat, J.2
Albanell, J.3
Rojo, F.4
Arribas, J.5
Baselga, J.6
-
27
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
-
28
-
-
0023733226
-
Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
-
Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988;8:5570-4.
-
(1988)
Mol Cell Biol
, vol.8
, pp. 5570-5574
-
-
Segatto, O.1
King, C.R.2
Pierce, J.H.3
Di Fiore, P.P.4
Aaronson, S.A.5
-
29
-
-
0035888069
-
Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology
-
Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int J Cancer 2001;94:185-91.
-
(2001)
Int J Cancer
, vol.94
, pp. 185-191
-
-
Egeblad, M.1
Mortensen, O.H.2
Jaattela, M.3
-
30
-
-
33744493376
-
Targeting tyrosine kinases in cancer: The second wave
-
Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science 2006;312:1175-8.
-
(2006)
Science
, vol.312
, pp. 1175-1178
-
-
Baselga, J.1
-
31
-
-
0027074588
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu
-
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res Treat 1992;24:85-95.
-
(1992)
Breast Cancer Res Treat
, vol.24
, pp. 85-95
-
-
Benz, C.C.1
Scott, G.K.2
Sarup, J.C.3
Johnson, R.M.4
Tripathy, D.5
Coronado, E.6
-
32
-
-
0035169666
-
Mechanism of action of trastuzumab and scientific update
-
Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001;28 Suppl 164-11.
-
(2001)
Semin Oncol
, vol.28
, Issue.SUPPL.
, pp. 164-111
-
-
Baselga, J.1
Albanell, J.2
Molina, M.A.3
Arribas, J.4
-
33
-
-
0025964104
-
The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain
-
Akiyama T, Matsudal S, Namba Y, Saito T, Toyoshima K, Yamamoto T. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 1991;11:833-42.
-
(1991)
Mol Cell Biol
, vol.11
, pp. 833-842
-
-
Akiyama, T.1
Matsudal, S.2
Namba, Y.3
Saito, T.4
Toyoshima, K.5
Yamamoto, T.6
-
34
-
-
31544465529
-
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer
-
Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12:424-31.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 424-431
-
-
Saez, R.1
Molina, M.A.2
Ramsey, E.E.3
Rojo, F.4
Keenan, E.J.5
Albanell, J.6
-
35
-
-
33751416678
-
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors
-
ABstract
-
Wong KK, Fracasso PM, Bukowski RM, Munster PN, Lynch T, Abbas R, et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. Proc Am Soc Clin Oncol 2006;24:ABstract 3018.
-
(2006)
Proc Am Soc Clin Oncol
, vol.24
, pp. 3018
-
-
Wong, K.K.1
Fracasso, P.M.2
Bukowski, R.M.3
Munster, P.N.4
Lynch, T.5
Abbas, R.6
-
36
-
-
33745574028
-
Early tumor response to Hsp90 therapy using HER-2 PET: Comparison with 18F-FDG PET
-
Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER-2 PET: Comparison with 18F-FDG PET. J. Nucl Med 2006;47:793-6.
-
(2006)
J. Nucl Med
, vol.47
, pp. 793-796
-
-
Smith-Jones, P.M.1
Solit, D.2
Afroze, F.3
Rosen, N.4
Larson, S.M.5
-
37
-
-
33749011681
-
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
-
Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006;7:270-7.
-
(2006)
Clin Breast Cancer
, vol.7
, pp. 270-277
-
-
Modi, S.1
D'Andrea, G.2
Norton, L.3
Yao, T.J.4
Caravelli, J.5
Rosen, P.P.6
-
38
-
-
0027468645
-
A truncated intracellular HER-2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells
-
Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, et al. A truncated intracellular HER-2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247-57.
-
(1993)
Mol Cell Biol
, vol.13
, pp. 2247-2257
-
-
Scott, G.K.1
Robles, R.2
Park, J.W.3
Montgomery, P.A.4
Daniel, J.5
Holmes, W.E.6
|